Table 2 Change in treatment and symptom scores anxiety patients at admission to the APCU
From: Emergency palliative cancer care: anxiety and midazolam
No anxiety (n = 45) | Mild anxiety (n = 57) | Moderate and severe anxiety (n = 62) | |
|---|---|---|---|
Benzodiazepine treatment during stay, n (%) | |||
No treatment | 31 (68.9) | 31 (54.4) | 23 (37.1) |
Unchanged | 6 (13.3) | 13 (22.8) | 16 (25.8) |
Started/increased oral benzodiazepines | 5 (11.1) | 6 (10.5) | 9 (14.5) |
Started/increased subcutaneous midazolam | 3 (6.7) | 7 (12.3) | 14 (22.6) |
Opioid treatment during stay, n (%) | |||
No change | 22 (48.9) | 23 (40.4) | 22 (35.5) |
Dose increased | 19 (42.2) | 28 (49.1) | 30 (48.4) |
Dose decreased | 4 (8.9) | 6 (10.5) | 10 (16.1) |
Anxiety development during stay, n (%) | |||
Deteriorated | 7 (15.6) | 5 (8.8) | 3 (4.8) |
Stable | 38 (84.4) | 39 (68.4) | 28 (45.2) |
Improved | N/A* | 13 (22.8) | 31 (50.0) |
Pain development during stay, n (%) | |||
Deteriorated | 3 (6.7) | 6 (10.5) | 7 (11.3) |
Stable | 29 (64.4) | 23 (40.4) | 37 (59.7) |
Improved | 13 (28.9) | 28 (49.1) | 18 (29.0) |
Dyspnoea development during stay, n (%) | |||
Deteriorated | 4 (8.9) | 5 (8.8) | 3 (4.8) |
Stable | 28 (62.2) | 37 (64.9) | 40 (64.5) |
Improved | 13 (28.9) | 15 (26.3) | 19 (30.6) |